In addition to its activities described here, EuroSIDA is also a founding partner of the newly-formed International Cohort Consortium of Infectious Disease (RESPOND). RESPOND is a non-interventional, non-randomised, open-label, multi-cohort observational study. The aim of RESPOND is to build a flexible and dynamic cohort consortium for the study of infectious diseases, including HIV and people at risk for HIV. 

EuroSIDA will be contributing patient data to RESPOND, together with other cohorts participating in the consortium.  In 2018, SHM will contribute pseudonymised data from a number of ATHENA patients for designated RESPOND projects, alongside those ATHENA cohort patients already included in EuroSida.

»Visit the REPOND website